https://www.selleckchem.com/pr....oducts/z-devd-fmk.ht
Severe hypomagnesemia post-cetuximab or panitumumab treatment was significantly associated with low baseline magnesium concentrations ( 1.8mg/dL; odds ratio 18.100, 95% confidence interval 1.570-210.000; p = 0.02 and low serum magnesium concentrations during treatment ( 1.1mg/dL; odds ratio 93.800, 95% confidence interval 3.510-2510.000; p = 0.007). To minimize the risk of severe hypomagnesemia during anti-EGFR treatment, magnesium replenishment should be initiated in patients with pre-replenishment concentrations of 1
Like
Comment
Share
